Faculty of Pharmacy, Department of Pharmacology, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India.
Department of Pharmacy, Banasthali Vidyapith, Rajasthan, India.
Neurochem Int. 2024 Jul;177:105761. doi: 10.1016/j.neuint.2024.105761. Epub 2024 May 7.
Alzheimer's disease (AD) remains one of the most formidable neurological disorders, affecting millions globally. This review provides a holistic overview of the therapeutic strategies, both conventional and novel, aimed at mitigating the impact of AD. Initially, we delve into the conventional approach, emphasizing the role of Acetylcholinesterase (AChE) inhibition, which has been a cornerstone in AD management. As our understanding of AD evolves, several novel potential approaches emerge. We discuss the promising roles of Butyrylcholinesterase (BChE) inhibition, Tau Protein inhibitors, COX-2 inhibition, PPAR-γ agonism, and FAHH inhibition, among others. The potential of the endocannabinoids (eCB) system, cholesterol-lowering drugs, metal chelators, and MMPs inhibitors are also explored, culminating in the exploration of the pivotal role of microRNA in AD progression. Parallel to these therapeutic insights, we shed light on the novel tools and methodologies revolutionizing AD research. From the quantitative analysis of gene expression by qRTPCR to the evaluation of mitochondrial function using induced pluripotent stem cells (iPSCs), the advances in diagnostic and research tools offer renewed hope. Moreover, we explore the current landscape of clinical trials, highlighting the leading drug interventions and their respective stages of development. This comprehensive review concludes with a look into the future perspectives, capturing the potential breakthroughs and innovations on the horizon. Through a synthesis of current knowledge and emerging research, this article aims to provide a consolidated resource for clinicians, researchers, and academicians in the realm of Alzheimer's disease.
阿尔茨海默病(AD)仍然是最具挑战性的神经退行性疾病之一,影响着全球数百万人。本综述提供了对治疗策略的全面概述,包括传统和新型策略,旨在减轻 AD 的影响。首先,我们深入探讨了传统方法,强调了乙酰胆碱酯酶(AChE)抑制的作用,这一直是 AD 管理的基石。随着我们对 AD 的理解不断发展,出现了几种有前途的新方法。我们讨论了丁酰胆碱酯酶(BChE)抑制、Tau 蛋白抑制剂、COX-2 抑制、过氧化物酶体增殖物激活受体-γ 激动剂和 FAHH 抑制等的潜在作用。内源性大麻素(eCB)系统、降胆固醇药物、金属螯合剂和 MMPs 抑制剂的潜力也在探索中,最终探讨了 microRNA 在 AD 进展中的关键作用。与这些治疗方法的见解并行,我们还介绍了革新 AD 研究的新型工具和方法学。从 qRT-PCR 对基因表达的定量分析到诱导多能干细胞(iPSCs)中对线粒体功能的评估,诊断和研究工具的进步带来了新的希望。此外,我们探讨了目前临床试验的现状,突出了领先的药物干预及其各自的开发阶段。本综述以对未来前景的展望结束,捕捉了即将出现的潜在突破和创新。通过综合当前的知识和新兴的研究,本文旨在为阿尔茨海默病领域的临床医生、研究人员和学者提供一个综合资源。